Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Bensimon G, Leigh PN, Tree T, Malaspina A, Payan CA, Pham HP, Klaassen P, Shaw PJ, Al Khleifat A, Amador MDM, Attarian S, Bell SM, Beltran S, Bernard E, Camu W, Corcia P, Corvol JC, Couratier P, Danel V, Debs R, Desnuelle C, Dimitriou A, Ealing J, Esselin F, Fleury MC, Gorrie GH, Grapperon AM, Hesters A, Juntas-Morales R, Kolev I, Lautrette G, Le Forestier N, McDermott CJ, Pageot N, Salachas F, Sharma N, Soriani MH, Sreedharan J, Svahn J, Verber N, Verschueren A, Yildiz O, Suehs CM, Saker-Delye S, Muller C, Masseguin C, Hajduchova H, Kirby J, Garlanda C, Locati M, Zetterberg H, Asselain B, Al-Chalabi A, MIROCALS Study Group

Open source

DOI: 10.1016/s0140-6736(25)00262-4
Published: 2025 May 24
Container: Lancet (London, England)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-00262-4,
  title = {Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.},
  author = {Bensimon G and Leigh PN and Tree T and Malaspina A and Payan CA and Pham HP and Klaassen P and Shaw PJ and Al Khleifat A and Amador MDM and Attarian S and Bell SM and Beltran S and Bernard E and Camu W and Corcia P and Corvol JC and Couratier P and Danel V and Debs R and Desnuelle C and Dimitriou A and Ealing J and Esselin F and Fleury MC and Gorrie GH and Grapperon AM and Hesters A and Juntas-Morales R and Kolev I and Lautrette G and Le Forestier N and McDermott CJ and Pageot N and Salachas F and Sharma N and Soriani MH and Sreedharan J and Svahn J and Verber N and Verschueren A and Yildiz O and Suehs CM and Saker-Delye S and Muller C and Masseguin C and Hajduchova H and Kirby J and Garlanda C and Locati M and Zetterberg H and Asselain B and Al-Chalabi A and MIROCALS Study Group},
  year = {2025},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(25)00262-4},
  url = {https://doi.org/10.1016/s0140-6736(25)00262-4}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
AU  - Bensimon G
AU  - Leigh PN
AU  - Tree T
AU  - Malaspina A
AU  - Payan CA
AU  - Pham HP
AU  - Klaassen P
AU  - Shaw PJ
AU  - Al Khleifat A
AU  - Amador MDM
AU  - Attarian S
AU  - Bell SM
AU  - Beltran S
AU  - Bernard E
AU  - Camu W
AU  - Corcia P
AU  - Corvol JC
AU  - Couratier P
AU  - Danel V
AU  - Debs R
AU  - Desnuelle C
AU  - Dimitriou A
AU  - Ealing J
AU  - Esselin F
AU  - Fleury MC
AU  - Gorrie GH
AU  - Grapperon AM
AU  - Hesters A
AU  - Juntas-Morales R
AU  - Kolev I
AU  - Lautrette G
AU  - Le Forestier N
AU  - McDermott CJ
AU  - Pageot N
AU  - Salachas F
AU  - Sharma N
AU  - Soriani MH
AU  - Sreedharan J
AU  - Svahn J
AU  - Verber N
AU  - Verschueren A
AU  - Yildiz O
AU  - Suehs CM
AU  - Saker-Delye S
AU  - Muller C
AU  - Masseguin C
AU  - Hajduchova H
AU  - Kirby J
AU  - Garlanda C
AU  - Locati M
AU  - Zetterberg H
AU  - Asselain B
AU  - Al-Chalabi A
AU  - MIROCALS Study Group
PY  - 2025
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(25)00262-4
UR  - https://doi.org/10.1016/s0140-6736(25)00262-4
ER  -

APA

G, B., PN, L., T, T., A, M., CA, P., HP, P., P, K., PJ, S., A, A. K., MDM, A., S, A., SM, B., S, B., E, B., W, C., P, C., JC, C., P, C., V, D., R, D., C, D., A, D., J, E., F, E., MC, F., GH, G., AM, G., A, H., R, J., I, K., G, L., N, L. F., CJ, M., N, P., F, S., N, S., MH, S., J, S., J, S., N, V., A, V., O, Y., CM, S., S, S., C, M., C, M., H, H., J, K., C, G., M, L., H, Z., B, A., A, A., & Group, M. S. (2025). Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(25)00262-4

Source records

pubmed · retrieved 2026-09-25T20:02:27.486Z
europe-pmc · retrieved 2026-09-25T20:02:27.694Z
hal · retrieved 2026-09-25T20:02:27.539Z